Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.

导出 LinkOut

翻译打印收藏纠错

第一作者： Mohmmed Tauseef,Sharip

第一单位： Department of Gastroenterology, Cambridge University Hospital NHS Foundation Trust, Cambridge CB2 0QQ, UK.

作者： Mohmmed Tauseef,Sharip ^[1] ; Nilanga,Nishad ^[1] ; Lushen,Pillay ^[1] ; Nilkantsingh,Goordoyel ^[1] ; Samuel,Goerge ^[1] ; Sreedhar,Subramanian ^[1]

作者单位： Department of Gastroenterology, Cambridge University Hospital NHS Foundation Trust, Cambridge CB2 0QQ, UK. ^[1]

关键词 Crohn’s disease anti-tumour necrosis factor antibody inflammatory bowel disease ustekinumab vedolizumab

DOI 10.3390/jcm13082187

PMID 38673459

发布时间 2024-04-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of clinical medicine

2024年13卷8期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.

Journal of clinical medicine

相似文献

Journal of clinical medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.

Journal of clinical medicine

相似文献

Journal of clinical medicine

相关期刊

检索历史清除